Recbio Technology Co., Ltd., a China-based biopharmaceutical company focusing on the development of vaccines, contracted a Europe-based CRO, OCT Clinical, to carry out its phase III clinical study for a SARS-CoV-2 vaccine.
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. The aim of the study is to evaluate the efficacy, safety, and immunogenicity of the ReCOV vaccine in healthy volunteers aged 18 years and older who have not been previously vaccinated against COVID-19 and have not been infected with COVID-19 in the past six months. While the overall enrollment target for this study is10,000 healthy volunteers, OCT Clinical will be responsible for enrolling 2,000 subjects at 11 research sites.
The study will be in good hands, given that conducting vaccine trials is one of OCT Clinical’s specialties. For instance, in 2021 OCT Clinical successfully completed the enrollment of 5,000 healthy volunteers for CanSino BIO, another Chinese biotech developing a COVID-19 vaccine.
'We are happy that we came across OCT Clinical to run the next phase of our clinical study. We have been impressed with the CRO’s portfolio and are counting on their professionalism and performance.' - Dr. Yong Liu, CEO, Recbio.
Irina Petrova at OCT Clinical commented, 'We are pleased that Recbio has trusted us with their clinical research needs, and we look forward to working together to conduct this vaccine study.'
The OCT Clinical team is responsible for a wide range of activities, including regulatory and logistics support, project management, volunteer recruitment and monitoring.
